Hot on the heels of the announcement that our new Immuno-Oncology panel is available for delivery, GenomeWeb interviewed Olink Proteomics CEO, Jon Heimer. The resulting article, “Olink Proteomics Expanding Biomarker Offerings, Exploring Development of Proprietary Markers” talks about the latest Proseek panel, our plans to further expand our biomarker assay offering during the next few months, and provides some insights into the longer term vision of the company.
Visit the GenomeWeb site to view the article >> (note: may require a GenomeWeb account for access)